Aromatase inhibitors from Broussonetia papyrifera

A composition consisting essentially of a compound selected from the group consisting of 5,7,2′,4′-tetrahydroxy-3-geranylflavone, isogemichalcone C, 3′-(γ-hydroxymethyl-(E)-γ-methylallyl)2,4,2′,4′-tetrahydroxychalcone 11′-O-coumarate, demethylmoracin 1,2S-2′,4′-dihydroxy-2′-(1-hydroxy-1-methylethyl)-dihydrofuro[2,3-h]flavanone, (2S) -2′,4′-dihydroxy-7-methoxy-8-prenylflavan, isolicoflavonol, (2S)-abyssinone II, (2S)-5,7,2′,4′-tetrahydroxyflavanone, (2S)-euchrenone a7, broussoflavonol F, (2S)-naringenin, broussonin A, 2,4,2′,4′-tetrahydroxy-3′-prenylchalcone, moracin N, albanol A, and mixtures thereof, and (b) an excipient.

A method of treating or preventing a medical condition mediated by aromatase activity comprising administering to an animal in need thereof a therapeutically effective amount of a compound that is present in an extract of Broussonetia papyrifera and that selectively inhibits aromatase activity.

A method of inhibiting the biosynthetic production of estrogen in a mammal comprising administering to the mammal a therapeutically effective amount of a compound that is present in an extract of Broussonetia papyrifera and that selectively inhibits aromatase activity.

A method of treating a hormone-dependent cancer comprising administering a pharmaceutical composition to a mammal in need thereof in a sufficient amount to suppress the initiation, promotion, or progression of the cancer, said composition comprising a compound selected from the group consisting of 5,7,2′,4′-tetrahydroxy-3-geranylflavone, isogemichalcone C, 3′-(γ-hydroxymethyl-(E)γ-methylallyl)2,4,2′,4′-tetrahydroxychalcone 11-O-coumarate, demethylmoracin 1,2S-2′,4′-dihydroxy-2″-(1-hydroxy-1-methylethyl)-dihydrofuro[2,3-h]flavanone, (2S)-2′,4′-dihydroxy-7-methoxy-8-prenylflavan, isolicoflavonol, (2S)-abyssinone II, (2S)-5,7,2′,4′-tetrahydroxyflavanone, (2S)-euchrenone a7, broussoflavonol F, (2S)-naringenin, broussonin A, 2,4,2′,4′-tetrahydroxy-3′-prenylchalcone, moracin N, albanol A, and mixtures thereof, and (b) an excipient.

A compound selected from the group consisting of 5,7,2′,4′-tetrahydroxy-3-geranylflavone, isogemichalcone C, 3′-(γ-hydroxymethyl-(E)γ-methylallyl)-2,4,2′,4′-tetrahydroxychalcone 11′-O-coumarate, demethylmoracin I, and (2S)-2′,4′-dihydroxy-2″-(1-hydroxy-1-methylethyl)-dihydrofuro[2,3-h]flavanone, 5,7,3′,4′-tetrahydroxy-6-geranylflavonol, 5,7,3′,4′-tetrahydroxy-3-methoxy-6-geranylflavone, (2S)-7,4′-dihydroxy-3′-prenylflavan, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)propane, 1-(2,4-dihydroxy-3-prenylphenyl)-3-(4-hydroxyphenyl)propane, and 1-(4-hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl)propane.